PMC:7029759 / 30376-30525 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"763","span":{"begin":6,"end":15},"obj":"Species"},{"id":"753","span":{"begin":87,"end":91},"obj":"Gene"}],"attributes":[{"id":"A753","pred":"tao:has_database_id","subj":"753","obj":"Gene:59272"},{"id":"A763","pred":"tao:has_database_id","subj":"763","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Thus, 2019-nCoV could be presented with an evolutionary trap when faced with potential ACE2-Fc therapy, leading toward a more benign clinical course."}

    LitCovid-PMC-OGER-BB

    {"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T466","span":{"begin":6,"end":15},"obj":"SP_7"},{"id":"T465","span":{"begin":87,"end":91},"obj":"G_3;PG_10;PR:000003622"}],"text":"Thus, 2019-nCoV could be presented with an evolutionary trap when faced with potential ACE2-Fc therapy, leading toward a more benign clinical course."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T306","span":{"begin":66,"end":71},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T307","span":{"begin":92,"end":94},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T308","span":{"begin":119,"end":120},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Thus, 2019-nCoV could be presented with an evolutionary trap when faced with potential ACE2-Fc therapy, leading toward a more benign clinical course."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T192","span":{"begin":0,"end":149},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Thus, 2019-nCoV could be presented with an evolutionary trap when faced with potential ACE2-Fc therapy, leading toward a more benign clinical course."}